BAP1 Loss Might Be a Predictive Biomarker for Immunotherapy Response in Pleural Mesothelioma

Thoracic Cancer 2026 July [Link] Reina Imase, Rie Sakakibara, Susumu Kirimura, Hironori Ishibashi, Kenichi Okubo, Yasunari Miyazaki Abstract Introduction: Reliable predictive biomarkers for immune checkpoint inhibitors (ICIs) in pleural mesothelioma (PM) are lacking. Loss of BRCA1-associated protein 1 (BAP1) is a frequent molecular alteration in PM and may influence the tumor immune microenvironment. We evaluated…

Read More

Impact of CD73/CD155 Expression on Survival in Resected Epithelial Pleural Mesothelioma: A Retrospective Single-center Study

In Vivo 2026 July-August [Link] Yusuke Nabe, Yasuhiro Fujita, Teppei Hashimoto, Kanji Tanaka, Takehiko Manabe, Katsuma Yoshimatsu, Yukiko Nemoto, Natsumasa Nishizawa, Rintaro Oyama, Yohei Honda, Masataka Mori, Hiroki Matsumiya, Masatoshi Kanayama, Akihiro Taira, Masaru Takenaka, Koji Kuroda, Shohei Shimajiri, Fumihiro Tanaka Abstract Background/aim: While CD73 and CD155 are implicated in immune evasion and tumor progression,…

Read More

Outcomes of Platinum Plus Pemetrexed and Treatment Patterns Following First-Line Nivolumab and Ipilimumab in Pleural Mesothelioma: Real-World Results From the German MesoNet Study

Clinical Lung Cancer 2026 July 2026 July [Link] Rajiv Shah, Eva L Buchmeier, Hans-Georg Kopp, Frank Griesinger, Martin Reck, Daniel C Christoph, Jonas Kuon, Nikolaj Frost, Christian Grohé, Martin Faehling, Felix C Saalfeld, Petra Hoffknecht, Jingting Luan, Julia Roeper, Paolo Chesi, Martin Kimmich, Till Olchers, Laura V Klotz, Inn Chung, Michael Thomas, Petros Christopoulos Abstract…

Read More

Outcomes of Platinum Plus Pemetrexed and Treatment Patterns Following First-Line Nivolumab and Ipilimumab in Pleural Mesothelioma: Real-World Results From the German MesoNet Study

Clinical Lung Cancer 2026 July [Link] Rajiv Shah, Eva L Buchmeier, Hans-Georg Kopp, Frank Griesinger, Martin Reck, Daniel C Christoph, Jonas Kuon, Nikolaj Frost, Christian Grohé, Martin Faehling, Felix C Saalfeld, Petra Hoffknecht, Jingting Luan, Julia Roeper, Paolo Chesi, Martin Kimmich, Till Olchers, Laura V Klotz, Inn Chung, Michael Thomas, Petros Christopoulos Abstract Background: There…

Read More

Metastatic pleural mesothelioma presenting as ulcerated submucosal colonic nodules

Journal of the American Association of Nurse Practitioners 2026 June 29 [Link] Shangwe Kiliaki, Kent Stevens Abstract Malignant pleural mesothelioma is a rare and aggressive malignancy associated with poor prognosis. Although it typically spreads through local invasion, distant metastasis to the gastrointestinal tract is uncommon, and colonic involvement is particularly rare. We report a case…

Read More

Dual-time-point [18F]FDG-PET/CT as a prognostic biomarker in patients with pleural mesothelioma undergoing immunotherapy

EJNMMI Research 2026 June 20 [Link] Solfrid Thunold, Eivor Hernes, Lars Tore Gyland Mikalsen, Saima Farooqi, Åsa Kristina Öjlert, Roslyn J Francis, Anna K Nowak, Weronika Maria Szejniuk, Søren Steen Nielsen, Susana Cedres, Marc Simo Perdigo, Jens Benn Sørensen, Carin Meltzer, Åslaug Helland, Eirik Malinen, Vilde Drageset Haakensen Abstract Background: [18F]FDG PET/CT provides a non-invasive…

Read More

CHIMERA: A Phase II Study of Neoadjuvant Pembrolizumab in Combination With Cisplatin or Carboplatin and Pemetrexed Followed by Surgery and Adjuvant Pembrolizumab in Resectable Pleural Mesothelioma

Clinical Lung Cancer 2026 July [Link] Giulia Pasello, Daniela Scattolin, Eleonora Faccioli, Paolo Andrea Zucali, Giuseppe Marulli, Federica Grosso, Giovanni Luca Ceresoli, Marcello Tiseo, Alessandra Bearz, Fabiana Letizia Cecere, Luana Calabrò, Francesco Callegarin, Paola Del Bianco, Gian Luca De Salvo, Federica Pezzuto, Fiorella Calabrese, Valentina Guarneri, Andrea Dell’Amore, Federico Rea Abstract Pleural mesothelioma (PM) is…

Read More

Trop-2 expression is associated with poor survival in pleural mesothelioma

Frontiers in Oncology 2026 May 29 [Link] Alejandro Aviles-Salas, Norma Hernández-Pedro, Enrique Caballé-Perez, José Lucio-Lozada, César Castillo-Ruiz, José Gregorio Chanona-Vilchis, Alejandro Aranda-Gutierrez, Mario Orozco-Morales, Pedro Barrios-Bernal, Rafael Parra-Medina, Luis Cabrera-Miranda, Andrés F Cardona, Oscar Arrieta Abstract Introduction: Pleural mesothelioma (PM) lacks reliable biomarkers to guide therapy. Trophoblast cell-surface antigen 2 (Trop-2) is targetable in epithelial…

Read More

Tumor treating fields in malignant pleural mesothelioma: from cytoskeletal collapse to immunophenotypic conversion

Frontiers in Oncology 2026 May 26 [Link] Xiaofeng Ma, Zhuo Zuo, Yulong Sun, Hong An Abstract The therapeutic efficacy in malignant pleural mesothelioma (MPM) is severely hindered by its dense stromal barrier and immunosuppressive microenvironment. Although Tumor Treating Fields (TTFields) have demonstrated significant survival benefits in clinical trials, their underlying mechanisms extend well beyond simple…

Read More

Ki67 proliferation index augments two-tier tumour grade in prediction of survival and progression-free survival in epithelioid pleural mesothelioma

ERJ Open Research 2026 June 8 [Link] Geraldine A Lynch, Yu Zhi Zhang, Nidhi Bhatt, Pia Charters, Avinash Aujayeb, Saru Walker, Jenny Symonds, Amelia O Clive, Rahul Bhatnagar, Anna Morley, Paul White, Andrew G Nicholson, Nick A Maskell, Anna Bibby Abstract Background: Pleural mesothelioma (PM) is a fatal asbestos-related cancer with a poor and often…

Read More